Becton, Dickinson and Company (NYSE:BDX) EVP Sells $11,243.56 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 74 shares of Becton, Dickinson and Company stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $151.94, for a total transaction of $11,243.56. Following the completion of the transaction, the executive vice president directly owned 21,159 shares of the company’s stock, valued at $3,214,898.46. This trade represents a 0.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total transaction of $13,638.00.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $151.56 on Tuesday. The firm has a market cap of $43.15 billion, a PE ratio of 24.72, a P/E/G ratio of 10.82 and a beta of 0.29. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a fifty day simple moving average of $162.67 and a two-hundred day simple moving average of $182.74.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same period in the previous year, the company posted $3.43 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.56 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of large investors have recently added to or reduced their stakes in the company. Activest Wealth Management grew its stake in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the last quarter. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth $25,000. SOA Wealth Advisors LLC. grew its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the last quarter. Steph & Co. raised its stake in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the last quarter. Finally, SHP Wealth Management purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at about $26,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BDX shares. Piper Sandler decreased their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research report on Friday, April 10th. They issued a “neutral” rating and a $167.00 price target for the company. Citigroup decreased their price objective on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Wells Fargo & Company dropped their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 10th. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $189.08.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.